Adam W Carrico1, Walter Gόmez2, Jennifer Jain3, Steven Shoptaw4, Michael V Discepola5, David Olem6, Justin Lagana-Jackson6, Rick Andrews5, Torsten B Neilands6, Samantha E Dilworth6, Jennifer L Evans6, William J Woods6, Judith T Moskowitz7. 1. Department of Public Health Sciences, University of Miami School of Medicine, 1120 NW 14th St., Office 1005, Miami, FL 33136 USA. Electronic address: a.carrico@miami.edu. 2. Berkeley School of Social Welfare, University of California, 120 Haviland Hall, #7400, Berkeley, CA 94720 USA. 3. Department of Medicine, Division of Global Public Health, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 902093 USA. 4. Departments of Family Medicine and Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, 10080 Wilshire Blvd., Los Angeles, CA 900024 USA. 5. San Francisco AIDS Foundation, 1035 Market Street, Suite 400, San Francisco, CA 94103 USA. 6. University of California, San Francisco School of Medicine, Box 0886, 550 16th Street, 3469, San Francisco, CA 94158 USA. 7. Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, 633 N. Saint Clair St., 19th Floor, Chicago, IL 60611 USA.
Abstract
BACKGROUND:Contingency management (CM) is an evidence-based intervention providing rewards in exchange for biomarkers that confirm abstinence from stimulants such as methamphetamine. We tested the efficacy of a positive affect intervention designed to boost the effectiveness of CM with HIV-positive, methamphetamine-using sexual minority men. METHODS: This attention-matched, randomized controlled trial of a positive affect intervention delivered during CM was registered on www.clinicaltrials.gov (NCT01926184). In total, 110 HIV-positive sexual minority men with biologically confirmed, recent methamphetamine use were enrolled. Five individual sessions of a positive affect intervention (n = 55) or an attention-control condition (n = 55) were delivered during three months of CM. Secondary outcomes examined over the 3-month intervention period included: 1) psychological processes relevant to affect regulation (i.e., positive affect, negative affect, and mindfulness); 2) methamphetamine craving; 3) self-reported stimulant use (past 3 months); and 4) cumulative number of urine samples that were non-reactive for stimulants (i.e., methamphetamine and cocaine) during CM. RESULTS: Those randomized to the positive affect intervention reported significant increases in positive affect during individual sessions and increases in mindfulness over the 3-month intervention period. Intervention-related improvements in these psychological processes relevant to affect regulation were paralleled by concurrent decreases in methamphetamine craving and self-reported stimulant use over the 3-month intervention period. CONCLUSIONS: Delivering a positive affect intervention may improve affect regulation as well as reduce methamphetamine craving and stimulant use during CM with HIV-positive, methamphetamine-using sexual minority men.
RCT Entities:
BACKGROUND: Contingency management (CM) is an evidence-based intervention providing rewards in exchange for biomarkers that confirm abstinence from stimulants such as methamphetamine. We tested the efficacy of a positive affect intervention designed to boost the effectiveness of CM with HIV-positive, methamphetamine-using sexual minority men. METHODS: This attention-matched, randomized controlled trial of a positive affect intervention delivered during CM was registered on www.clinicaltrials.gov (NCT01926184). In total, 110 HIV-positive sexual minority men with biologically confirmed, recent methamphetamine use were enrolled. Five individual sessions of a positive affect intervention (n = 55) or an attention-control condition (n = 55) were delivered during three months of CM. Secondary outcomes examined over the 3-month intervention period included: 1) psychological processes relevant to affect regulation (i.e., positive affect, negative affect, and mindfulness); 2) methamphetamine craving; 3) self-reported stimulant use (past 3 months); and 4) cumulative number of urine samples that were non-reactive for stimulants (i.e., methamphetamine and cocaine) during CM. RESULTS: Those randomized to the positive affect intervention reported significant increases in positive affect during individual sessions and increases in mindfulness over the 3-month intervention period. Intervention-related improvements in these psychological processes relevant to affect regulation were paralleled by concurrent decreases in methamphetamine craving and self-reported stimulant use over the 3-month intervention period. CONCLUSIONS: Delivering a positive affect intervention may improve affect regulation as well as reduce methamphetamine craving and stimulant use during CM with HIV-positive, methamphetamine-using sexual minority men.
Authors: Gbenga O Ogedegbe; Carla Boutin-Foster; Martin T Wells; John P Allegrante; Alice M Isen; Jared B Jobe; Mary E Charlson Journal: Arch Intern Med Date: 2012-01-23
Authors: Steven Shoptaw; Cathy J Reback; James A Peck; Xiaowei Yang; Erin Rotheram-Fuller; Sherry Larkins; Rosemary C Veniegas; Thomas E Freese; Christopher Hucks-Ortiz Journal: Drug Alcohol Depend Date: 2004-11-28 Impact factor: 4.492
Authors: Sarah Bowen; Neharika Chawla; Susan E Collins; Katie Witkiewitz; Sharon Hsu; Joel Grow; Seema Clifasefi; Michelle Garner; Anne Douglass; Mary E Larimer; Alan Marlatt Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Danita Jemison; Sequoia Jackson; Olorunleke Oni; Deva Cats-Baril; Shawdae Thomas-Smith; Abigail Batchelder; Allan Rodriguez; Samantha E Dilworth; Lisa R Metsch; Deborah Jones; Daniel J Feaster; Conall O'Cleirigh; Gail Ironson; Adam W Carrico Journal: AIDS Behav Date: 2019-09
Authors: Janelle M Painter; Jasmine Mote; Andrew D Peckham; Erica H Lee; Timothy R Campellone; Jennifer G Pearlstein; Stefana Morgan; Ann M Kring; Sheri L Johnson; Judith T Moskowitz Journal: Gen Hosp Psychiatry Date: 2019-07-23 Impact factor: 3.238
Authors: David Olem; Maya Earle; Walter Gómez; Lara Coffin; Paul Cotten; Jennifer P Jain; Judith T Moskowitz; Adam W Carrico Journal: Cogn Behav Pract Date: 2020-11-10
Authors: Delaram Ghanooni; Adam W Carrico; Renessa Williams; Tiffany R Glynn; Judith T Moskowitz; Savita Pahwa; Suresh Pallikkuth; Margaret E Roach; Samantha Dilworth; Bradley E Aouizerat; Annesa Flentje Journal: Psychosom Med Date: 2022-08-16 Impact factor: 3.864
Authors: Hema R Kondur; Tae K Lee; Roger McIntosh; Hetta Gouse; Robert Paul; Christian Grov; Dietmar Fuchs; Walter Gómez; Samantha E Dilworth; Torsten B Neilands; Adam W Carrico Journal: J Neurovirol Date: 2022-07-12 Impact factor: 3.739
Authors: Massy Mutumba; Judith T Moskowitz; Torsten B Neilands; Ji-Young Lee; Samantha E Dilworth; Adam W Carrico Journal: PLoS One Date: 2021-05-18 Impact factor: 3.752
Authors: Denise C Vidot; Jennifer A Manuzak; Nichole R Klatt; Suresh Pallikkuth; Margie Roach; Samantha E Dilworth; Savita Pahwa; Adam W Carrico Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.771
Authors: Ji-Young Lee; Jae Eun Lee; Judith T Moskowitz; Daniel J Feaster; Torsten B Neilands; Samantha E Dilworth; Allan Rodriguez; Adam W Carrico Journal: Drug Alcohol Depend Date: 2021-06-03 Impact factor: 4.852
Authors: Jeremy D Kidd; Margaret M Paschen-Wolff; Amy A Mericle; Billy A Caceres; Laurie A Drabble; Tonda L Hughes Journal: J Subst Abuse Treat Date: 2021-06-16